Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 147Gastrointestinal 12CNS 6Tumor-Agnostic 4Genitourinary 4Thoracic 3Other hematologic neoplasm 3Lymphoid 3Sarcoma 2Plasma cell 2Head & Neck 2Gynecologic 2Endocrine 2Other solid neoplasm 1NET 1Myeloid 1Dermatologic 1Classical hematology 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Hemangiosarcoma 1

Interventions

Radiotherapy 137Cyclophosphamide 132Temozolomide 116Doxorubicin 99Filgrastim 68Ifosfamide 64Gemcitabine 58Etoposide 55Bevacizumab 51Imatinib Mesylate 50fludarabine phosphate 49Irinotecan 46pembrolizumab 45Peripheral Blood Stem Cell Transplantation 45pazopanib 43Magnetic Resonance Spectroscopy 42Methotrexate 40Carboplatin 40Busulfan 40Vincristine 38Surgical Procedures, Operative 37Nivolumab 37Melphalan 37Cisplatin 36Radiation 34Blood Specimen Collection 33Mycophenolic Acid 31Cyclosporine 31Docetaxel 29Trabectedin 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × pertuzumab × Sarcoma × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

OHSU Knight Cancer Institute

Phase EARLY_PHASE1 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡